secwatch.observer — SEC 8-K summary
======================================

Issuer:     Dianthus Therapeutics, Inc. /DE/ (DNTH)
CIK:        0001690585
Form:       8-K
Filed at:   2026-06-12T11:00:32+00:00
Accession:  0001690585-26-000029
Event type: other_material
Sentiment:  neutral
Materiality: 0.50
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Dianthus posts corporate presentation with Phase 3 CAPTIVATE interim data for claseprubart in CIDP
--------------------------------------------------------------------------------

- Interim responder analysis data for first 40 patients from Part A of Phase 3 CAPTIVATE trial of claseprubart in chronic inflammatory demyelinating polyneuropathy.
- Presentation posted on investor relations website on June 11, 2026.
- No specific numeric results disclosed in the filing text; actual data is in the presentation slides.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1690585/000169058526000029/0001690585-26-000029-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1690585/000169058526000029/dnth-20260612.htm
  HTML page:      https://secwatch.observer/filing/0001690585-26-000029

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer